DMW - Deutsche Medizinische Wochenschrift, Table of Contents Dtsch Med Wochenschr 2011; 136(31/32): 1598-1600DOI: 10.1055/s-0031-1281562 Rheumatologie | CommentaryRheumatologie© Georg Thieme Verlag KG Stuttgart · New YorkSchmerztherapie bei rheumatologischen ErkrankungenTreatment of pain in rheumatic diseasesF. Luttosch1 , C. Baerwald1 1Sektion Rheumatologie, Department für Innere Medizin, Neurologie und Dermatologie, Universitätsklinikum Leipzig Recommend Article Abstract Buy Article(opens in new window) Schlüsselwörter Schmerztherapie - rheumatoide Arthritis - nichtsteroidale Antirheumatika Keywords pain management - rheumatoid arthritis - non-steroidal anti-inflammatory drugs Full Text References Literatur 1 Baerwald C, Verdecchia P, Duquesroix B. et al . Efficacy, safety, and effects on blood pressure of naproxcinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip: a randomized, double-blind, parallel-group, multicenter study. Arthritis Rheum. 2010; 62 3635-3644 2 Becker G, Blum H. Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus. Lancet. 2009; 373 1198-206 3 Bolten W. Neubewertung der NSAR im dreistufigen WHO-Schmerztherapie-Schema. Arthritis Rheuma. 2011; 31 89-98 4 Chan F, Lanas A, Scheiman J. et al . Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010; 376 173-179 5 Hale M, Upmalis D, Okamoto A. et al . Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. Curr Med Res Opin. 2009; 25 1095-1104 6 Karlsson J, Pivodic A, Aguirre D. et al . Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee. J Rheumatol. 2009; 36 1290-1297 7 Laine L, Curtis S, Cryer B. et al . Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34,701 arthritis patients. Aliment Pharmacol Ther. 2010; 32 1240-1248 8 Lane N, Schnitzer T, Birbara C. et al . Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. 2010; 363 1521-1531 9 McDougall J. Arthritis and pain. Neurogenic origin of joint pain. Arthritis Res Ther. 2006; 8 220 10 Trelle S, Reichenbach S, Wandel S. et al . Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. Brit Med J. 2011; 342 c7086 11 Van der Linden M, Gaugris S, Kuipers E. et al . COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors. Pharmacoepidemiol Drug Saf. 2009; 18 880-890 12 Vauth C, Greiner W. Kosten in der Schmerztherapie. Gesundh ökon Qual manag. 2011; 16 S3-S9 Dr. Franziska Luttosch Sektion Rheumatologie/GerontologieDepartment für Innere Medizin, Neurologie und DermatologieUniversitätsklinikum Leipzig Liebigstr. 20 04103 Leipzig Phone: 0341/9724710 Fax: 0341/9724709 Email: franziska.luttosch@medizin.uni-leipzig.de
